• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus.

作者信息

Chia Yvonne M F, Teng Tiew-Hwa K, Tay Wan T, Anand Inder, MacDonald Michael R, Yap Jonathan, Chandramouli Chanchal, Richards A Mark, Tromp Jasper, Ouwerkerk Wouter, Ling Lieng H, Lam Carolyn S P

机构信息

Singapore General Hospital, Singapore.

National Heart Centre Singapore, Singapore.

出版信息

Eur J Heart Fail. 2019 May;21(5):685-688. doi: 10.1002/ejhf.1467. Epub 2019 Apr 29.

DOI:10.1002/ejhf.1467
PMID:31033098
Abstract
摘要

相似文献

1
Prescription patterns of anti-diabetic medications and clinical outcomes in Asian patients with heart failure and diabetes mellitus.亚洲心力衰竭合并糖尿病患者的抗糖尿病药物处方模式及临床结局
Eur J Heart Fail. 2019 May;21(5):685-688. doi: 10.1002/ejhf.1467. Epub 2019 Apr 29.
2
Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas.射血分数降低型心力衰竭：亚洲地区与欧美地区患者特征和临床结局比较。
Eur J Heart Fail. 2019 May;21(5):577-587. doi: 10.1002/ejhf.1347. Epub 2018 Dec 10.
3
Changes in the Prescription of Glucose-Lowering Medications in Patients With Type 2 Diabetes Mellitus After a Cardiovascular Event: A Call to Action From the DATAFILE Study.心血管事件后 2 型糖尿病患者降糖药物处方的变化：来自 DATAFILE 研究的行动呼吁。
J Am Heart Assoc. 2019 Jul 16;8(14):e012244. doi: 10.1161/JAHA.119.012244. Epub 2019 Jul 4.
4
Prescribing patterns of evidence-based heart failure pharmacotherapy and outcomes in the ASIAN-HF registry: a cohort study.基于证据的心力衰竭药物治疗的处方模式和 ASIAN-HF 注册研究的结果：一项队列研究。
Lancet Glob Health. 2018 Sep;6(9):e1008-e1018. doi: 10.1016/S2214-109X(18)30306-1.
5
Add-on therapy in metformin-treated patients with type 2 diabetes at moderate cardiovascular risk: a nationwide study.二甲双胍治疗的 2 型糖尿病中伴有中度心血管风险患者的附加治疗：一项全国性研究。
Cardiovasc Diabetol. 2020 Jul 6;19(1):107. doi: 10.1186/s12933-020-01078-5.
6
Risk of Death and Heart Failure among Patients with Type 2 Diabetes Treated by Metformin and Nonmetformin Monotherapy: A Real-World Study.二甲双胍单药与非二甲双胍单药治疗 2 型糖尿病患者的死亡风险和心力衰竭风险：一项真实世界研究。
J Diabetes Res. 2021 Jun 10;2021:5534387. doi: 10.1155/2021/5534387. eCollection 2021.
7
Effects on Clinical Outcomes of Adding Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas to Metformin Therapy in Patients With Type 2 Diabetes Mellitus.在 2 型糖尿病患者中，与磺酰脲类药物相比，添加二肽基肽酶-4 抑制剂对临床结局的影响。
Ann Intern Med. 2015 Nov 3;163(9):663-72. doi: 10.7326/M15-0308. Epub 2015 Oct 13.
8
Contemporary Treatment Patterns and Clinical Outcomes of Comorbid Diabetes Mellitus and HFrEF: The CHAMP-HF Registry.合并糖尿病与射血分数降低心衰（HFrEF）患者的当代治疗模式与临床结局：CHAMP-HF 注册研究。
JACC Heart Fail. 2020 Jun;8(6):469-480. doi: 10.1016/j.jchf.2019.12.015. Epub 2020 May 6.
9
Prescribing patterns and adherence to medication among South-Asian, Chinese and white people with type 2 diabetes mellitus: a population-based cohort study.南亚、华裔和白人2型糖尿病患者的用药模式及药物依从性：一项基于人群的队列研究。
Diabet Med. 2014 Dec;31(12):1586-93. doi: 10.1111/dme.12559. Epub 2014 Sep 15.
10
International variation in characteristics and clinical outcomes of patients with type 2 diabetes and heart failure: Insights from TECOS.泰西多研究：2 型糖尿病合并心力衰竭患者的特征和临床结局的国际差异
Am Heart J. 2019 Dec;218:57-65. doi: 10.1016/j.ahj.2019.08.016. Epub 2019 Aug 28.

引用本文的文献

1
Effect of Luseogliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, and Dipeptidyl-Peptidase 4 Inhibitors on the Quality-of-Life and Treatment Satisfaction of Patients With Type 2 Diabetes Mellitus: A Subanalysis of a Multicenter, Open-Label, Randomized-Controlled Trial (J-SELECT Study).钠-葡萄糖协同转运蛋白2抑制剂鲁格列净与二肽基肽酶4抑制剂对2型糖尿病患者生活质量和治疗满意度的影响：一项多中心、开放标签、随机对照试验的亚组分析（J-SELECT研究）
Diabetes Ther. 2024 Jun;15(6):1403-1416. doi: 10.1007/s13300-024-01575-w. Epub 2024 Apr 24.
2
Effect of canagliflozin on N-terminal pro-brain natriuretic peptide in patients with type 2 diabetes and chronic heart failure according to baseline use of glucose-lowering agents.根据基线时降糖药物的使用情况，评估卡格列净对 2 型糖尿病合并慢性心力衰竭患者 N 末端脑利钠肽前体的影响。
Cardiovasc Diabetol. 2021 Sep 3;20(1):175. doi: 10.1186/s12933-021-01369-5.
3
Heart Failure With Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction.2 型糖尿病合并心力衰竭：降糖药物、血糖控制与射血分数的关系。
Front Endocrinol (Lausanne). 2020 Jul 10;11:448. doi: 10.3389/fendo.2020.00448. eCollection 2020.
4
Prescription patterns of diabetes medications influencing clinical outcomes of heart failure patients with reduced ejection fraction.影响射血分数降低的心力衰竭患者临床结局的糖尿病药物处方模式。
ESC Heart Fail. 2020 Apr;7(2):604-615. doi: 10.1002/ehf2.12617. Epub 2020 Jan 29.